Composition for treating lung cancer, particularly of non-small lung cancers (NSCLC)

A kit comprising at least five different immunostimulatory compositions, wherein the at least five different immunostimulatory compositions are:

• (a) an immunostimulatory composition comprising an isolated NY-ESO-1 antigen coding RNA comprising a globin 3′ untranslated region (3′UTR);
• (b) an immunostimulatory composition comprising an isolated MAGE-C1 antigen coding RNA comprising a globin 3′UTR;
• (c) an immunostimulatory composition comprising an isolated MAGE-C2 antigen coding RNA comprising a globin 3′UTR;
• (d) an immunostimulatory composition comprising an isolated 5T4 antigen coding RNA comprising a globin 3′UTR;
• and
• (e) an immunostimulatory composition comprising an isolated Survivin antigen coding RNA comprising a globin 3′UTR.

A kit comprising at least five different immunostimulatory compositions, wherein the at least five different immunostimulatory compositions are:

• (a) an immunostimulatory composition comprising an isolated NY-ESO-1antigen coding RNA comprising a G/C content of the antigen coding region that is increased compared to the G/C content of a wild-type RNA encoding the antigen;
• (b) an immunostimulatory composition comprising an isolated MAGE-C1 antigen coding RNA comprising a G/C content of the antigen coding region that is increased compared to the G/C content of a wild-type RNA encoding the antigen;
• (c) an immunostimulatory composition comprising an isolated MAGE-C2 antigen coding RNA comprising a G/C content of the antigen coding region that is increased compared to the G/C content of a wild-type RNA encoding the antigen;
• (d) an immunostimulatory composition comprising an isolated 5T4 antigen coding RNA comprising a G/C content of the antigen coding region that is increased compared to the G/C content of a wild-type RNA encoding the antigen;
• and
• (e) an immunostimulatory composition comprising an isolated Survivin antigen coding RNA comprising a G/C content of the antigen coding region that is increased compared to the G/C content of a wild-type RNA encoding the antigen.

A kit comprising at least five different immunostimulatory compositions, wherein the at least five different immunostimulatory compositions are:

• (a) an immunostimulatory composition comprising an isolated NY-ESO-1 antigen coding RNA comprising a 5′ untranslated region (5′UTR) and/or a 3′ untranslated region (3′UTR) that is modified compared to a wild-type RNA encoding the antigen;
• (b) an immunostimulatory composition comprising an isolated MAGE-C1 antigen coding RNA comprising a 5′UTR and/or a 3′UTR that is modified compared to a wild-type RNA encoding the antigen;
• (c) an immunostimulatory composition comprising an isolated MAGE-C2 antigen coding RNA comprising a 5′UTR and/or a 3′UTR that is modified compared to a wild-type RNA encoding the antigen;
• (d) an immunostimulatory composition comprising an isolated 5T4 antigen coding RNA comprising a 5′UTR and/or a 3′UTR that is modified compared to a wild-type RNA encoding the antigen;
• and
• (e) an immunostimulatory composition comprising an isolated Survivin antigen coding RNA comprising a 5′UTR and/or a 3′UTR that is modified compared to a wild-type RNA encoding the antigen.